Companies developing peroxisome proliferator-activated receptor (PPAR) agonists, like Avandia, are urged to conduct two-year carinogenicity evaluations.

• 研发过氧物酶增殖子活化的受体（PPAR）激动剂，类似文迪雅的公司，要求做两年的基因评价。